GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2
WEB1 day ago · GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.
Zantac’s Developer Settles Lawsuits Claiming Cancer Link
WEB1 day ago · The Food and Drug Administration asked in 2020 that all Zantac products, which relied on a heartburn drug developed by GSK, be taken off the market. The current Zantac 360 uses a different active ...
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln
WEB1 day ago · GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 …
WEB1 day ago · (Reuters) -GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company ...
GSK Rises After Settling Zantac Cases for Up to $2.2 Billion
WEB1 day ago · (Bloomberg) -- GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court cases alleging that its old reflux medication Zantac was ...
GSK shares jump on $2.2 billion Zantac settlement | Reuters
WEB1 day ago · GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.
Zantac maker GSK agrees to pay $2.3 bn in US settlements
WEB1 day ago · British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer.
GSK reaches $2.2bn heartburn medication Zantac settlement in US
WEB1 day ago · GSK has reached a $2.2bn settlement to resolve the vast majority of cases linked to its heartburn medicine Zantac, in a move that will help assuage legal concerns overhanging the UK drugmaker.
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits
WEB1 day ago · GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine Zantac causes cancer.
UK firm GSK to pay $2.2bn over Zantac cancer claims - BBC
WEB1 day ago · UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.
- Some results have been removed